PE20190398A1 - Anticuerpos nuevos que se unen especificamente a los epitopos del virus del zika y usos de los mismos - Google Patents
Anticuerpos nuevos que se unen especificamente a los epitopos del virus del zika y usos de los mismosInfo
- Publication number
- PE20190398A1 PE20190398A1 PE2019000034A PE2019000034A PE20190398A1 PE 20190398 A1 PE20190398 A1 PE 20190398A1 PE 2019000034 A PE2019000034 A PE 2019000034A PE 2019000034 A PE2019000034 A PE 2019000034A PE 20190398 A1 PE20190398 A1 PE 20190398A1
- Authority
- PE
- Peru
- Prior art keywords
- zika virus
- specifically bind
- epithopes
- zika
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/18—Togaviridae; Flaviviridae
- G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/10—Detection of antigens from microorganism in sample from host
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Referido a un anticuerpo y fragmento de union a antigeno del mismo, que se unen especificamente a los epitopos del virus del zika (ZIKV) que neutralizan potentemente la infeccion por el virus del zika o se dirigen contra la proteina no estructural 1 (NS1) del virus del zika. Tambien refiere los sitios antigenicos a los que se une el citado anticuerpo, tal como el dominio III de la proteina envolvente del virus que comprende la secuencia SEQ ID NO:401 o 407. Dicho anticuerpo comprende una cadena pesada donde, al menos, una CDRH3 comprende en una secuencia de aminoacidos seleccionado de SEQ ID NO: 3, 75, 39, 21, 57, 239, entre otros. Asimismo, divulga los acidos nucleicos que codifican e inmortalizan las celulas B que producen dichos anticuerpos. Siendo utiles en metodos de analisis, en diagnostico, profilaxis y tratamiento de la infeccion por zika
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2016/066684 WO2018010789A1 (en) | 2016-07-13 | 2016-07-13 | Novel antibodies specifically binding to zika virus epitopes and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20190398A1 true PE20190398A1 (es) | 2019-03-13 |
Family
ID=56413654
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2019000034A PE20190398A1 (es) | 2016-07-13 | 2017-07-12 | Anticuerpos nuevos que se unen especificamente a los epitopos del virus del zika y usos de los mismos |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US11117954B2 (es) |
| EP (2) | EP3484915B1 (es) |
| JP (2) | JP7252888B2 (es) |
| KR (1) | KR102595764B1 (es) |
| CN (2) | CN109563157B (es) |
| AU (1) | AU2017297757B2 (es) |
| BR (1) | BR112018074456A2 (es) |
| CA (1) | CA3024374A1 (es) |
| CL (2) | CL2019000067A1 (es) |
| CO (1) | CO2019001111A2 (es) |
| CR (1) | CR20190066A (es) |
| DK (1) | DK3484915T5 (es) |
| DO (2) | DOP2019000006A (es) |
| EA (1) | EA201990243A1 (es) |
| EC (1) | ECSP19009170A (es) |
| ES (1) | ES2959883T3 (es) |
| FI (1) | FI3484915T3 (es) |
| HR (1) | HRP20231196T1 (es) |
| HU (1) | HUE063272T2 (es) |
| IL (1) | IL262710B2 (es) |
| LT (1) | LT3484915T (es) |
| MX (1) | MX2019000526A (es) |
| MY (1) | MY190553A (es) |
| PE (1) | PE20190398A1 (es) |
| PH (1) | PH12018502348B1 (es) |
| PL (1) | PL3484915T3 (es) |
| SG (1) | SG11201809879WA (es) |
| SI (1) | SI3484915T1 (es) |
| UA (1) | UA126381C2 (es) |
| WO (2) | WO2018010789A1 (es) |
| ZA (1) | ZA201807467B (es) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3485028A1 (en) | 2016-07-13 | 2019-05-22 | Evonik Degussa GmbH | Method of separating lipids from a lysed lipids containing biomass |
| CA3040189A1 (en) | 2016-10-13 | 2018-04-19 | Massachusetts Institute Of Technology | Antibodies that bind zika virus envelope protein and uses thereof |
| WO2019042555A1 (en) | 2017-08-31 | 2019-03-07 | Humabs Biomed Sa | MULTISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO ZIKA VIRUS EPITOPES AND USES THEREOF |
| EP3527664A1 (en) | 2018-02-15 | 2019-08-21 | Evonik Degussa GmbH | Method of isolating lipids from a lipids containing biomass |
| JP2019152666A (ja) * | 2018-03-02 | 2019-09-12 | 富士レビオ株式会社 | ジカウイルスを検出する方法及びキット |
| CA3098373A1 (en) | 2018-04-24 | 2019-10-31 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Potent zika virus-specific and cross-neutralizing monoclonal antibodies to zika and dengue viruses following zikv infection or vaccination |
| BR112020023222A2 (pt) | 2018-05-15 | 2021-03-23 | Evonik Operations Gmbh | método de isolamento de lipídios a partir de uma biomassa contendo lipídios lisados por inversão por emulsão |
| CN112166176B (zh) | 2018-05-15 | 2024-06-25 | 赢创运营有限公司 | 借助疏水性二氧化硅从含有脂质的生物质中分离脂质的方法 |
| WO2020061159A1 (en) * | 2018-09-20 | 2020-03-26 | Vanderbilt University | Human antibodies to zika virus |
| WO2020078568A1 (en) * | 2018-10-19 | 2020-04-23 | Humabs Biomed Sa | Antibodies and methods for treatment of lyssavirus infection |
| US20220017605A1 (en) * | 2018-10-31 | 2022-01-20 | Icahn School Of Medicine At Mount Sinai | Human antibodies targeting zika virus ns1, ns1 polypeptides and uses thereof |
| EP3883961A1 (en) | 2018-11-20 | 2021-09-29 | Takeda Vaccines, Inc. | Novel anti-zika virus antibodies and uses thereof |
| WO2020245663A1 (en) * | 2019-06-01 | 2020-12-10 | Institut Pasteur | Nanobody-based ns1 assay for the specific diagnosis of acute zika virus infection |
| WO2021050989A1 (en) * | 2019-09-13 | 2021-03-18 | Duke University | Zika antibodies and their use |
| WO2021089055A1 (zh) * | 2019-11-07 | 2021-05-14 | 中国科学院微生物研究所 | 一种寨卡/登革疫苗及其应用 |
| KR20220103761A (ko) * | 2019-11-19 | 2022-07-22 | 벤더르빌트 유니버시티 | 지카 바이러스를 중화하는 인간 항체 및 이의 사용 방법 |
| CN111138534B (zh) * | 2019-12-31 | 2021-09-28 | 武汉班科生物技术股份有限公司 | 寨卡病毒囊膜蛋白的鼠源单克隆抗体 |
| CN111100201B (zh) * | 2019-12-31 | 2021-09-28 | 武汉班科生物技术股份有限公司 | 针对寨卡病毒囊膜蛋白的鼠源单克隆抗体 |
| JP7471555B2 (ja) * | 2020-02-20 | 2024-04-22 | 国立感染症研究所長 | フラビウイルス交差中和抗体及び医薬組成物 |
| JP2023527169A (ja) | 2020-05-20 | 2023-06-27 | タケダ ワクチン，インコーポレイテッド | 抗原の効力を決定するための方法 |
| EP4153222A1 (en) | 2020-05-20 | 2023-03-29 | Takeda Vaccines, Inc. | Method for detection of zika virus specific antibodies |
| WO2021236225A1 (en) | 2020-05-20 | 2021-11-25 | Takeda Vaccines, Inc. | Method for detection of zika virus specific antibodies |
| CN115697392A (zh) * | 2020-06-28 | 2023-02-03 | 神州细胞工程有限公司 | 一种降低病毒ade效应的方法 |
| WO2022212858A2 (en) * | 2021-04-01 | 2022-10-06 | A2 Biotherapeutics, Inc. | Polypeptides targeting hla-a*11 and methods of use thereof |
| CN112921124B (zh) * | 2021-04-08 | 2021-09-28 | 广东创晟控股集团有限公司 | 一种快速检测病毒的试剂盒 |
| WO2024211789A1 (en) * | 2023-04-07 | 2024-10-10 | Fred Hutchinson Cancer Center | Cross-flavivirus binding domains and uses thereof |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3766162A (en) | 1971-08-24 | 1973-10-16 | Hoffmann La Roche | Barbituric acid antigens and antibodies specific therefor |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4233402A (en) | 1978-04-05 | 1980-11-11 | Syva Company | Reagents and method employing channeling |
| JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| EP0098110B1 (en) | 1982-06-24 | 1989-10-18 | NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD | Long-acting composition |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4831175A (en) | 1986-09-05 | 1989-05-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
| US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
| US20020102208A1 (en) | 1999-03-01 | 2002-08-01 | Paul Chinn | Radiolabeling kit and binding assay |
| MY133346A (en) | 1999-03-01 | 2007-11-30 | Biogen Inc | Kit for radiolabeling ligands with yttrium-90 |
| AU2003263853A1 (en) * | 2002-08-16 | 2004-03-03 | Board Of Regents The University Of Texas System | Compositions and methods related to flavivirus envelope protein domain iii antigens |
| EP1597280B2 (en) * | 2003-02-26 | 2016-08-24 | Institute for Research in Biomedicine | Monoclonal antibody production by ebv transformation of b cells |
| AU2004252171B2 (en) | 2003-06-27 | 2011-04-21 | Biogen Ma Inc. | Modified binding molecules comprising connecting peptides |
| WO2008143954A2 (en) | 2007-05-14 | 2008-11-27 | Biogen Idec Ma Inc. | Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto |
| US9347043B2 (en) * | 2008-10-22 | 2016-05-24 | Institute For Research In Biomedicine | Methods for producing antibodies from plasma cells |
| EP3689902B1 (en) * | 2013-03-15 | 2023-06-28 | Dana-Farber Cancer Institute, Inc. | Flavivirus neutralizing antibodies and methods of use thereof |
| WO2017156511A1 (en) | 2016-03-11 | 2017-09-14 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Live attenuated zika virus vaccine |
| US20170298119A1 (en) * | 2016-04-15 | 2017-10-19 | Visterra, Inc. | Antibody molecules to zika virus and uses thereof |
| TW201815821A (zh) | 2016-07-18 | 2018-05-01 | 美商再生元醫藥公司 | 抗茲卡病毒抗體及使用方法 |
| EP4438117A3 (en) | 2017-07-28 | 2024-12-18 | Takeda Pharmaceutical Company Limited | Tyk2 inhibitors and uses thereof |
-
2016
- 2016-07-13 WO PCT/EP2016/066684 patent/WO2018010789A1/en not_active Ceased
-
2017
- 2017-07-12 PE PE2019000034A patent/PE20190398A1/es unknown
- 2017-07-12 EP EP17742985.9A patent/EP3484915B1/en active Active
- 2017-07-12 WO PCT/EP2017/067581 patent/WO2018011283A1/en not_active Ceased
- 2017-07-12 JP JP2019501482A patent/JP7252888B2/ja active Active
- 2017-07-12 US US16/317,533 patent/US11117954B2/en not_active Expired - Fee Related
- 2017-07-12 EA EA201990243A patent/EA201990243A1/ru unknown
- 2017-07-12 BR BR112018074456-5A patent/BR112018074456A2/pt not_active IP Right Cessation
- 2017-07-12 DK DK17742985.9T patent/DK3484915T5/da active
- 2017-07-12 UA UAA201901101A patent/UA126381C2/uk unknown
- 2017-07-12 CR CR20190066A patent/CR20190066A/es unknown
- 2017-07-12 ES ES17742985T patent/ES2959883T3/es active Active
- 2017-07-12 HR HRP20231196TT patent/HRP20231196T1/hr unknown
- 2017-07-12 KR KR1020197004192A patent/KR102595764B1/ko active Active
- 2017-07-12 CA CA3024374A patent/CA3024374A1/en active Pending
- 2017-07-12 CN CN201780042888.7A patent/CN109563157B/zh active Active
- 2017-07-12 CN CN202211721078.3A patent/CN116199775A/zh active Pending
- 2017-07-12 EP EP23191207.2A patent/EP4342911A1/en not_active Withdrawn
- 2017-07-12 PH PH1/2018/502348A patent/PH12018502348B1/en unknown
- 2017-07-12 MY MYPI2018704108A patent/MY190553A/en unknown
- 2017-07-12 AU AU2017297757A patent/AU2017297757B2/en not_active Expired - Fee Related
- 2017-07-12 SI SI201731420T patent/SI3484915T1/sl unknown
- 2017-07-12 IL IL262710A patent/IL262710B2/en unknown
- 2017-07-12 HU HUE17742985A patent/HUE063272T2/hu unknown
- 2017-07-12 FI FIEP17742985.9T patent/FI3484915T3/fi active
- 2017-07-12 LT LTEPPCT/EP2017/067581T patent/LT3484915T/lt unknown
- 2017-07-12 MX MX2019000526A patent/MX2019000526A/es unknown
- 2017-07-12 PL PL17742985.9T patent/PL3484915T3/pl unknown
- 2017-07-12 SG SG11201809879WA patent/SG11201809879WA/en unknown
-
2018
- 2018-11-07 ZA ZA2018/07467A patent/ZA201807467B/en unknown
-
2019
- 2019-01-08 DO DO2019000006A patent/DOP2019000006A/es unknown
- 2019-01-09 CL CL2019000067A patent/CL2019000067A1/es unknown
- 2019-02-05 CO CONC2019/0001111A patent/CO2019001111A2/es unknown
- 2019-02-07 EC ECSENADI20199170A patent/ECSP19009170A/es unknown
-
2021
- 2021-02-10 DO DO2021000026A patent/DOP2021000026A/es unknown
- 2021-06-01 US US17/335,792 patent/US11912757B2/en active Active
- 2021-06-01 US US17/335,799 patent/US20210363227A1/en not_active Abandoned
- 2021-11-12 CL CL2021002994A patent/CL2021002994A1/es unknown
-
2023
- 2023-02-10 JP JP2023019144A patent/JP2023062036A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20190398A1 (es) | Anticuerpos nuevos que se unen especificamente a los epitopos del virus del zika y usos de los mismos | |
| AR103868A1 (es) | Anticuerpos anti-cd47 como agentes terapéuticos | |
| MX2020006213A (es) | Anticuerpos anti-trem2 y metodos relacionados. | |
| EA202191751A1 (ru) | Гуманизированное антитело против pd-1 человека | |
| PE20181054A1 (es) | Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion | |
| AR101875A1 (es) | Proteína de unión a antígenos, bi-específicos del receptor anti-cgrp / receptor pac1 y usos de las mismas | |
| PE20190737A1 (es) | Anticuerpos anti-cd27 | |
| PE20180927A1 (es) | Moleculas de union a lag-3 y metodos de uso de las mismas | |
| PE20181451A1 (es) | Anticuerpos neutralizadores del virus de inmunodeficiencia humana | |
| CO2020002060A2 (es) | Anticuerpos multiespecíficos que se unen específicamente a los epítopos del virus del zika y usos de los mismos | |
| MX2017012802A (es) | Anticuerpos antisortilina y métodos para su uso. | |
| EA201890874A1 (ru) | Антитела, которые эффективно нейтрализуют вирус гепатита в, и их применение | |
| PE20181270A1 (es) | Anticuerpo que neutraliza el virus respiratorio sincitial humano | |
| ES2687282T3 (es) | Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos | |
| MX366359B (es) | Anticuerpos humanizados contra la molecula de adhesion celular relacionada al antigeno carcinoembrionico 1 (ceacam1). | |
| AR096617A1 (es) | Anticuerpos anti-tweakr y sus usos | |
| PH12021550521A1 (en) | Antibodies that potently neutralize rabies virus and other lyssaviruses and uses thereof | |
| AR109683A1 (es) | Anticuerpos contra el factor xi y sus usos | |
| MX2021012984A (es) | Anticuerpos y metodos para el tratamiento de la infeccion por influenza a. | |
| PE20180576A1 (es) | ANTICUERPOS MONOCLONALES ESPECIFICOS PARA EL ANTIGENO P DEL VIRUS RESPIRATORIO SINCICIAL HUMANO (VRSh), PRODUCIDOS Y SECRETADOS POR HIBRIDOMAS CELULARES, UTILES PARA LA DETECCION Y EL DIAGNOSTICO DE LA INFECCION CAUSADA POR VRSh | |
| PE20141683A1 (es) | Anticuerpos monoclonales especificos para el antigeno m2-1 del virus respiratorio sincicial (vrs) | |
| PE20171734A1 (es) | Anticuerpos monoclonales especificos del antigeno m del virus metapneumovirus humano (hmpv) y su uso en un metodo de diagnostico | |
| AR099604A1 (es) | Anticuerpos de metaloproteinasa de matriz 9 y sus métodos de uso | |
| CR20210462A (es) | Anticuerpos anti-trem1 y métodos relacionados | |
| AR108451A1 (es) | Anticuerpos anti-tenascina modificados y métodos de utilización |